The second hit: Comorbidities in systemic lupus erythematosus

Future Rheumatology

Volumn 2, Issue 5, 2007, Pages 497-506

  Pineau, Christian A ^a   Lee, Chin ^b,c   Ramsey Goldman, Rosalind ^b   Clarke, Ann E ^a   Bernatsky, Sasha ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Comorbidities; Malignancy; Osteoporosis; Systemic lupus erythematosus

Indexed keywords

ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBRINOGEN; HEPARIN; IMMUNOSUPPRESSIVE AGENT; LUPUS ANTICOAGULANT; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN D;

BONE MINERALIZATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EXPOSURE; DRUG SAFETY; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIFE EXPECTANCY; LUNG CANCER; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 35548972013     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.5.497     Document Type: Review

References (85)

1. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: Bimodal mortality pattern of systemic lupus erythernatosus. Am. J. Med. 60(2), 221-225 (1976).
2. Petri M, Spence D, Bone LR, Hochberg MC: Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 71(5), 291-302 (1992).
3. Manzi S, Meilahn EN, Rairie JE et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 145(5), 408-415 (1997).
4. Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J. Rheumatol. 26(10), 2137-2143 (1999).
5. Esdaile JM, Abrahamowicz M, Grodzicky T et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44(10), 2331-2337 (2001).
6. Urowitz MB, Ibanez D, Gladman DD: Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J. Rheumatol. 34(1), 70-75 (2007).
7. Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42(2), 338-346 (1999).
8. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR: Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am. J. Cardiol. 93(2), 198-200 (2004).
9. Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am. J Med. 58(2), 243-264 (1975).
10. Haider YS, Roberts WC: Coronary arterial disease in systemic lupus erythematosus: quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am. J. Med. 70(4), 775-781 (1981).
11. Panchal L, Divate S, Vaideeswar P, Pandit SP: Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 patients in India. J. Postgrad. Med. 52(1), 5-10 (2006).
12. Bruce IN, Gladman DD, Ibanez D, Urowitz MB: Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II: predictive factors for perfusion abnormalities. J. Rheumatol. 30(2), 288-291 (2003)
13. Sella EM, Sato EI, Leite WA, Oliveira Filho JA. Barbieri A: Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann. Rheum. Dis. 62(11), 1066-1070 (2003).
14. Manzi S, Selzer F, Sutton-Tyrrell K et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42(1), 51-60 (1999).
15. Roman MJ, Shanker B, Davis A et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349(25), 2399-2406 (2003).
16. Asanuma Y, Oeser A, Shintani AK et al.: Premature coronary-artery atherosclerosis in systemic lupus crythematosus. N. Engl. J. Med. 349(25), 2407-2415 (2003).
17. Chung CP, Oeser A, Avalos I, Raggi P, Stein CM: Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus. Lupus 15(9), 562-569 (2006).
18. Manger K, Kusus M, Forster C et al.: Factors associated with coronary artery calcification in young female patients with SLE. Ann. Rheum. Dis. 62(9), 846-850 (2003).
19. Manger K, Manger B, Repp R et al.: Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann. Pheum. Dis. 61(12), 1065-1070 (2002).
20. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G: Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 27(3), 685-691 (2000).
21. Alamanos Y. Voulgari PV, Papassava M, Tsamandouraki K, Drosos AA: Survival and mortality rates of systemic lupus erythematosus patients in northwest Greece. Study of a 21-year incidence cohort. Rheumatology 42(12), 1582 (2003).
22. Petri M, Perez-Hutthann S, Spence D, Hochberg MC: Risk factors for coronary artery disem in patients with systemic lupus erythematosus. Am. J. Med. 93(5), 513-519 (1992).
23. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 48(11), 3159-3167 (2003).
24. Rahman P. Urowitz MB, Gladman DD, Bruce IN, Genest J: Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J. Rheumatol. 26(11), 2363-2368(1999).
25. Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data-analysis. Am. J. Med. 96(3). 254-259 (1994).
26. Rahman P, Gladman DD, Urowitz MB: Premature coronary artery disease in systemic lupus erythematosus in the absence of corticosteroid use. J. Rheumatol. 27(5), 1323-1325 (2000).
27. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN: The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol. 26(2), 325-330 (1999).
28. Farzaneh-Far A, Roman MJ, Lockshin MD et al.: Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 54(12), 3918-3925 (2006).
29. Badui E, Garciarubi D, Robles E et al.: Cardiovascular manifestations in systemic lupus erythematosus - prospective study of 100 patients. Angiology 36(7), 431-441 (1985).
30. Costedoat-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC: Anti-SSA/ Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res. Ther. 7(2), 69-73 (2005).
31. Lazzerini PE, Acampa M, Guided F et al.: Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum. 50(4), 1248-1252 (2004).
32. Chen CY, Wang FL, Lin CC: Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin. Toxicol. 44(2), 173-175 (2006).
33. Cardoso CR, Sales MA, Papi JA, Salles GF: QT-interval parameters are increased in systemic lupus erythematosus patients. Lupus 14(10), 846-852 (2005).
34. Calvo-Alen J, Alarcon GS, Tew MB et al.: Systemic lupus erythematosus in a multiethnic US cohort XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. Arthritis Rheum. 54(6), 1940-1945 (2006).
35. Barnes EV, Narain S, Naranjo A et al.: High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14(8), 576-582 (2005).
36. Szalai AJ, Alarcon GS, Calvo-Alen J et al.: Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology 44(7), 864-868 (2005).
37. Asanuma Y, Chung CP, Oeser A et al.: Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol. 33(3), 539-545 (2006).
38. Ames PR, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GR: Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J. Rheumatol. 27(5), 1190-1195 (2000).
39. Yee CS, Crabtree N, Skan J et al.: Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann. Rheum. Dis. 64(1), 111-113 (2005).
40. Redlich K, Ziegler S, Kiener HP et al.: Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann. Rheum. Dis. 59(4), 308-310 (2000).
41. Kalla AA, Fataar AB, Jessop SJ, Bewerunge L: Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum. 36(12), 1726-1734 (1993).
42. Sinigaglia L, Varenna M, Binelli L. et al.: Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J. Rheumatol. 26(6), 1280-1284 (1999).
43. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD: Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13(6), 436-441 (2004).
44. Teichmann J, Lange U, Stracke H, Federlin K, Bretzel RG: Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol. Int. 18(4), 137-140 (1999).
45. Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E: Three year follow up of bone mineral density change in premenopausal women with systemic lupus erythematosus. J. Rheumatol. 26(2), 310-317 (1999).
46. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA: Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology 39(4), 389-392 (2000).
47. Boyanov M, Popivanov P, Gentchev G: Assessment of forearm volumetric bone mineral density from standard areal densitometry data. J. Clin. Densitom. 5(4), 391-402 (2002).
48. Ramsey-Goldman R, Dunn JE, Huang CF et al.: Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 42(5), 882-890 (1999).
49. Bultink IEM, Lems WF, Kostense PJ, Dijkmans BAC, Voskuyl AE: Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 52(7), 2044-2050 (2005).
50. Lee C, Almagor O, Dunlop DD et al.: Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 57(4), 585-592 (2007).
51. Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can. Med. Assoc. J. 167(10), S1-S34 (2002).
52. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N: Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. Rheumatol. 28(1), 102-108 (2001).
53. Becker A, Fischer R, Scherbaum WA, Schneider M: Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 10(11), 809-814 (2001).
54. Sinigaglia L, Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Fantini F: Bone mass in systemic lupus erythematosus. Clin. Exp. Rheumatol. 18(5), S27-S34 (2000).
55. Ibanez D, Urowitz MB, Gladman DD: Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J. Rheumatol. 30(9), 1977-1982 (2003).
56. Kipen Y, Strauss BJG, Morand EF: Body composition in systemic lupus erythematosus. Br. J. Rheumatol. 37(5), 514-519 (1998).
57. Gilboe IM, Kvien TK, Haugeberg G, Husby G: Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann. Rheum. Dis. 59(2), 110-115 (2000).
58. Gordon C, Crabtree N, Skan J, Bowman S, Situnayake D: Prevalence and predictors of osteoporotic fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 44(Suppl.), S334 (2001).
59. Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E: Bone mineral density in women with systemic lupus erythematosus. Clin. Rheumatol. 21(2), 135-141 (2002).
60. Pons F, Peris P, Guanabens N et al.: The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women. Br. J. Rheumatol. 34(8), 742-746 (1995).
61. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, de Deuxchaisnes CN: Trabecular and cortical bone loss in systemic lupus erythematosus. Br. J. Rheumatol. 35(3), 244-247 (1996).
62. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E: Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J. Rheumatol. 24(10), 1922-1929 (1997).
63. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI - a disease-activity index for lupus patients. Arthritis Rheum. 35(6), 630-640 (1992).
64. Pineau CA, Bernatsky S, Abrahamowicz M et al.: A comparison of retrospective and prospective evaluations of the the systemic lupus international collaborating clinics/American College of Rheumatology Damage Index (SLICC/ACR DI). Arthritis Rheum. 48(9), S189 (2003).
65. Lee C, Almagor O, Dunlop DD et al.: Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology 45(1), 53-60 (2006).
66. Bernatsky S, Boivin JF, Joseph L et al.: An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 52(5), 1481-1490 (2005).
67. Bin J, Bernatsky S, Gordon C et al.: Lung cancer in systemic lupus erythematosus. Lung Cancer 56(3), 303-306 (2007).
68. Ognenovski VM, Marder W, Somers EC et al.: Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J. Rheumatol. 31(9), 1763-1767 (2004).
69. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 50(11), 3619-3625 (2004).
70. Bernatsky S, Ramsey-Goldman R, Gordon C et al.: Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology 43(11), 1386-1389 (2004).
71. Bernatsky S, Boivin JF, Joseph L et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum. 54(8), 2550-2557 (2006).
72. Smedby KE, Hjalgrim H, Askling J et al.: Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J. Natl. Cancer Inst. 98(1), 51-60 (2006).
73. Bernatsky S, Ramsey-Goldman R, Isenberg D et al.: Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology 46(5), 830-832 (2007).
74. Landgren O, Engels EA, Pfeiffer RMN et al.: Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case - control study in Scandinavia. J. Natl. Cancer Inst. 98(18), 1321-1330 (2006).
75. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D: Risk of multiple myeloma following medication use and medical conditions: a case - control study in Connecticut women. Cancer Epidemiol. Biomarkers Prev. 15(12), 2342-2347 (2006).
76. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR: Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case - control study. Int. J. Cancer 118(12), 3095-3098 (2006).
77. Lovstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE: A closer look at non Hodgkin's lymphoma cases in a national Swedish Systemic Lupus Erythematosus cohort - a nested case - control study. Ann. Rheum. Dis. DOI:10.1136/ard.2006.067108 (2007) (Epub ahead of print).
78. Bernatsky S, Ramsey-Goldman R, Rajan R et al.: Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann. Rheum. Dis. 64(10), 1507-1509 (2005).
79. King JK, Costenbader KH: Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin. Rheumatol. 26(9), 1491-1494 (2007).
80. Kojima M, Itoh H, Shimizu K et al.: Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int. J. Surg. Pathol. 14(1), 43-48 (2006).
81. Bernatsky S, Boivin JF, Joseph L et al.: The relationship between cancer and medication exposures in systemic lupus erythematosus: a case - cohort study. Ann. Rheum. Dis. (2007) (In Press).
82. Bernatsky S, Rahme E, Lee J: Non-Hodgkin's lymphoma: meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology 46(4), 690-694 (2007).
83. Ruiz-Irastorza G, Ugarte A, Egurbide MV et al.: Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann. Rheum. Dis. 66(6), 815-817 (2007).
84. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepidemiol. Drug Saf. 16(3), 241-249 (2007).
85. ACOG Practice Bulletin Number 45, August 2003: Committee on Practice Bulletins - Gynecology. Cervical Cytology Screening. Obstet. Gynecol. 102(2), 417-427 (2003).